SCH-497079: A Comprehensive Review of its Development and Discontinuation

1. Introduction to SCH-497079

1.1. Overview and Identification

SCH-497079 is identified as an investigational small molecule drug.[1] It is also referred to by the synonym SCH 497079.[1] The primary pharmacological target of SCH-497079 is the Histamine H3 receptor (H3R), for which it acts as an antagonist.[1] This initial identification frames SCH-497079 as a compound designed to modulate the histaminergic system, with potential therapeutic implications stemming from the diverse roles of H3 receptors in the central nervous system and periphery.

1.2. Originator and Developer

The development of SCH-497079 was primarily attributed to Merck Sharp & Dohme Corp. (also referred to as Merck & Co.).[1] Schering-Plough is also significantly associated with its development, particularly noted in the context of its H3 receptor antagonist properties and clinical trials for obesity.[3] The timeline of SCH-497079's development coincides with the merger of Merck & Co. and Schering-Plough Corp., which was announced in March 2009 and completed later that year.[5] This corporate integration is a pertinent factor, as such events often lead to reviews and reprioritization of research and development pipelines. The discontinuation of SCH-497079 during its Phase 2 clinical development could have been influenced not only by scientific findings regarding its efficacy and safety but also by strategic decisions made in the wake of this major pharmaceutical merger. Other entities listed as inactive organizations in its development include Merck GmbH and Merck Sharp & Dohme LLC.[1]

1.3. Drug Class